TP53 and neoplasm: Currently, the most well-characterized component of MYC-induced tumor suppression involves the tumor suppressor P19/ARF (ARF)/E3 ubiquitin-protein ligase MDM2 (MDM2)/TP53 pathway, which leads to the activation of an apoptotic response that is dependent on the TP53 protein [25,26,27].